We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
Cap. Flow
+$64.9M
Cap. Flow %
3.27%
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65
Avg Time Held Equity + Options
4.7 quarters
Top 10 Avg Time Held Equity + Options
5.1 quarters
Top 20 Avg Time Held Equity + Options
6.3 quarters
Avg Time Held Equity only
4.9 quarters
Top 10 Avg Time Held Equity only
5.1 quarters
Top 20 Avg Time Held Equity only
6.4 quarters

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$46.6M
2
PBYI icon
Puma Biotechnology
PBYI
+$41M
3
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$35.9M
4
CORI
Corium International, Inc.
CORI
+$19M
5
ISRG icon
Intuitive Surgical
ISRG
+$17.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$37.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.2M
3
NVRO icon
NEVRO CORP.
NVRO
+$20.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.3M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.26%
2 Miscellaneous 3.45%
3 Consumer Staples 0.19%
4 Consumer Discretionary 0.06%
5 Energy 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ACHC icon
126
Acadia Healthcare
ACHC
$2.81B
– –
-1
Closed – –
ACRS icon
127
Aclaris Therapeutics
ACRS
$511M
– –
-1,260,847
Closed -$37.6M –
AGEN icon
128
Agenus
AGEN
$314M
– –
-183
Closed -$14K –
AMGN icon
129
Amgen
AMGN
$223B
– –
-20,000
Closed -$3.28M –
AORT icon
130
Artivion
AORT
$1.04B
– –
-123
Closed -$2K –
APVO icon
131
Aptevo Therapeutics
APVO
$3.13M
– –
0
– -$1K
2016 Q3
3 quarters
ARCT icon
132
Arcturus Therapeutics
ARCT
$342M
– –
-1,301
Closed -$10K –
ATRC icon
133
AtriCure
ATRC
$2.89B
– –
-55
Closed -$1K –
BIO icon
134
Bio-Rad Laboratories Class A
BIO
$9.73B
– –
-49,416
Closed -$9.85M –
BMRN icon
135
BioMarin Pharmaceuticals
BMRN
$10.5B
– –
-250
Closed -$22K –
BSX icon
136
Boston Scientific
BSX
$62.8B
– –
-3
Closed – –
CAPR icon
137
Capricor Therapeutics
CAPR
$400M
– –
-400
Closed -$13K –
CERS icon
138
Cerus
CERS
$455M
– –
-740
Closed -$3K –
CLDX icon
139
Celldex Therapeutics
CLDX
$2.22B
– –
-465
Closed -$25K –
DHR icon
140
Danaher
DHR
$157B
– –
-3
Closed – –
ELV icon
141
Elevance Health
ELV
$92.2B
– –
-3,081
Closed -$510K –
EVH icon
142
CALL
Evolent Health
EVH
$520M
– –
-50,000
Closed -$190K –
ILMN icon
143
Illumina
ILMN
$40.9B
– –
-3,598
Closed -$597K –
IVV icon
144
iShares Core S&P 500 ETF
IVV
$897B
– –
-1
Closed – –
IWS icon
145
iShares Russell Mid-Cap Value ETF
IWS
$15.3B
– –
-2
Closed – –
MASI icon
146
DELISTED
Masimo
MASI
– –
-5,945
Closed -$554K –
MCK icon
147
McKesson
MCK
$112B
– –
-3,601
Closed -$534K –
NERV icon
148
Minerva Neurosciences
NERV
$120M
– –
-101,317
Closed -$6.57M –
PAHC icon
149
Phibro Animal Health
PAHC
$1.49B
– –
-18,382
Closed -$517K –
HIND icon
150
Vyome Holdings
HIND
$13.8M
– –
0
– –
2017 Q1
1 quarter
4 5
6
7 8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $64.9M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.

  • Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
  • Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
  • Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
  • Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
  • Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.